Back

ATYR1923-C-004

Official Title

202207111

Study Details

The purpose of the study is to determine if 2 different doses of efzofitimod verses placebo given intravenously every 4 weeks can reduce steroid need in patients with pulmonary sarcoidosis, and subsequently improve quality of life.

Principal Investigator

Dr. Adam Anderson

IRB Number

202207111

Eligibility

1. Participants must be 18 to 75 years old
2. Participants must have had pulmonary sarcoidosis for at least 6 months and must currently have symptoms

Compensation is provided (contact the study team for compensation amount).

Volunteer Information

For more information about this study, contact Volunteer for Health at:

Back